Combination treatment of neurological disorders

The combination treatment with NMDA receptor antagonists and GABAB receptor agonists addresses the limitations of current therapies by targeting multiple brain pathways, enhancing efficacy and safety in treating neurological disorders.

WO2025137661A1PCT designated stage expired Publication Date: 2025-06-26BIOHAVEN THERAPEUTICS LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/061617
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-28
Filing Date
2024-12-22
Publication Date
2025-06-26

AI Technical Summary

Technical Problem

Current treatments for neurological disorders are inadequate in addressing the underlying pathophysiological mechanisms and often result in significant side effects, limiting their efficacy and safety.

Method used

A combination treatment approach involving the use of specific compounds, such as NMDA receptor antagonists and GABAB receptor agonists, to target multiple pathways in the brain, thereby modulating neurotransmitter activity and reducing excitotoxicity.

Benefits of technology

This approach enhances therapeutic efficacy by improving symptom management and reducing side effects, providing a safer and more effective treatment for neurological disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024061617_26062025_PF_FP_ABST
    Figure US2024061617_26062025_PF_FP_ABST
Patent Text Reader

Abstract

A method of treating a depressive disorder, or a neurological or neurodegenerative disorder in a subject includes administering to the subject a therapeutically effective amount of a Kv7 channel activator of Formula I, or a pharmaceutically acceptable salt thereof, in combination with a prodrug of an NMDA receptor antagonist of Formula II, or a pharmaceutically acceptable salt thereof: Formula I, Formula II. A pharmaceutical composition including the Kv7 channel activator and the prodrug of the NMDA receptor antagonist is also disclosed.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] -- - , ,.. ... , . ,,.. . , , , , , , , ,. .. ... , . . + .. . - , . , . . , , ., , .. , , , , . -- - , , , , , , ,-4, - . . * . . .,,,,. –., ., . –. , . ., ,,, , . –.., . ., .,,,, ,. -- - ,,,. –. , , ., . . –.. . ,,, , ., ., . , –. , ,,. , ., , . –. , ., , , ., . -. . . , . ,,,, , .. . . . . ..,, .,, . . -- - , . ,, . . , “” “” “”, “” “. “ ”” . . “ - -- . , ” “ ” .., . , . , - “ ” ,,, . “ ” . , .., 1, , , . ,..,-. . , . -- - . , , , ,, , , ,. . , “ ”. , . . , , , , , , , , , , , , ,, , , , , , , , , , , , , , , , ,- , , -, . , , ,,.-.2n- ,., ,, ,. . . -, , ,. “ ” . “ , , ” ,.., ,. , , , , - .. “ ” “ ,” , , -- -“ ” ,. “ ” , ” “.” “ ” - . “- ,, , , - ,, ,. , “ ”, “ ” . ,. , , , , ", " “ . . ” , , , ,, . , . , ,, . . , . , . , . .., ..,, , -- - ., , . , , , . , . , , , -4. - , , - , ,..,1,2,,41. 2,11–27,-7.. ,7, ,., 22,--. . 2 . 4. . ,.4. -- - , , , . “ . . -- - , - , , , , , ., , , , , , , , , , ., ,, , , , , , , , , , ,,, ,. , . ,, . , . ”, . . . , , , , , , - ,, , , . , , ,. . ., . ., ,, , . - ..., , -- - . ,, . , ,. , ,, , , , , , ,- , , , , , , , , , , , , ,, , , , ’, ,' ,, , - , ,,, , , ,, , , , ,. , ' , ’ , , ,, , , , , . . , , ,, ,, , . , , , - , -- - . , . , , . . , , .. , . . ,, , , . , , , . . . , . , , , .. , ,. . ., . . -- - . , . , ,. , . , . ,,.., ,. ,, ,, , , ,, ,.., . . , . , , , , , , , , , , , , , , , . , . ,, , , , , . . - .

[0002] -- - . ,,, ,,, , , . ,. , , ,-,. . . ,.., , . , . , - . ,..,-, ..-... - ... . , . . , . ,.., . , , . . -- - - .., , . ' - . , - . - ~ . . - , , -, ., - ,. . - , , , , , . , . . . . ,~ , . - -. .,. - , , - . ,,, . , =,,,.,,,,,,,,, .. –. - . , . ., -- - . - . , , . = - . ., = , . . , ,.., . - - . - , . - ,..., .. ,*, , - . ,.., - , .. . - .. . =, =,, , , ,, . - .- , . . , .-, -- - , =... , – ., . . ,- ., . , , =, , , . , ..- , .- , ,.., ,. . . , , . , . , , .-. , , , -- - . , .-. -- - .. - .- ,- - , , ,, ..,- . . , . - . , - =,. =, , -,.,, , ... . . - .. , =, , = .-..,-, ,. , . , -. . . -- -, , , , , .

Claims

-- - . , , , ,, , , ,- 4 - - . . , , , , , , ,, - , , ,, , . . , , , ,-- - ,, ,-4- . . , , ,, , , , , ,- , ,, , , , , , , , , , , , , , ,, , , ’, ' , , , - , , , , , , , , , , , , , ' , , . ’ , . , . . , .-- - . , . . , . . ,. , .-- - . , .. ,,. . , . . , , .-- - . , , , , ,,4- , ,-4-, . . , , ,-- -. ,. . ,. . ,-- - ., .

Citation Information

Patent Citations

  • NMDA antagonist prodrugs

    US20190152914A1

  • KV7 channel activators compositions and methods of use

    WO2019183148A1